Skip to main content

Omission of SLNB Feasible for Younger Patients With ER+/cN0 Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on May 28, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 28, 2024 -- A novel natural language understanding (NLU) pipeline can identify the rates of lymphedema and node positivity among women with estrogen receptor-positive (ER+), clinically node-negative (cN0) breast cancer, according to a study published online May 22 in JCO Clinical Cancer Informatics.

Neil Carleton, from the UPMC Hillman Cancer Center in Pittsburgh, and colleagues developed and applied a novel NLU model to examine rates of pathological node positivity (pN+) and rates of lymphedema to assess whether omission of routine axillary staging could be extended to younger patients with ER+/cN0 disease. Data were included for all patients with early-stage ER+, cN0 breast cancer who had sentinel lymph node biopsy (SLNB).

Using the NLU approach, 925 patients aged 55 years or older were identified. The researchers found that the NLU model yielded strong results for breast and arm lymphedema identification, with sensitivity of 100 percent and specificity of 93 percent. The model accrued 93 percent accuracy per patient. Comparison of the NLU model with the Cancer Registry yielded a similar number of patients and no significant differences in the rates of pN+ across ages and clinical T stages. Equally low rates of SLN positivity were seen across ages for patients with clinical stage T1a, T1b, and T1c disease, with higher rates of total lymphedema than rates of pN+.

"These data suggest that the Choosing Wisely recommendation to omit SLNB might be extended to a younger cohort of patients with ER+/cN0 disease," the authors write.

One author is a cofounder of Realyze Intelligence, which provided technology used in the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Some Women in Their 40s Prefer to Delay Breast Cancer Screening

MONDAY, July 15, 2024 -- A considerable proportion of women aged 39 to 49 years prefer to delay breast cancer screening, especially after a decision aid (DA) intervention...

NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians

FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...

Acupuncture Reduces Endocrine Symptoms, Hot Flashes in Breast Cancer

MONDAY, June 24, 2024 -- A 10-week acupuncture intervention significant reduces endocrine symptoms and hot flashes among women with breast cancer receiving endocrine therapy (ET)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.